This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Mar 2012

Particle Sciences Acquires LyoCell Technology

Particle Sciences will offer the technology to clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds.

US-based pharmaceutical CRO Particle Sciences, Inc. (PSI) has acquired exclusive rights to Lyotropics Therapeutics’ LyoCell patent portfolio.

 

The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds, both small and large molecule.
 
Under the revenue-share agreement, PSI obtains a full license to the technology except for compounds previously developed by Lyotropics. Particle Sciences will offer the technology to clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds.
 
Robert Lee, PSI’s vice president of Pharmaceutical Development, said, “LyoCells are proprietary lyotropic liquid crystal-based formulations that contain both

Related News